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Trigeminal neuralgia is a common disorder caused mainly by compression of the trigeminal nerve root by an
overlying blood vessel. Pharmacotherapy and surgery are ineffective or unsuitable in many patients. Therefore,
other therapeutic modalities have been tried, including injection of botulinum toxin type A (BTX-A). This study aims
to systematically review the therapeutic efficacy and safety of BTX-A in trigeminal neuralgia. PubMed, EMBASE,
Cochrane Library Clinical Trials and Web of Science from January 1966 to March 2013 were searched with the terms
of “botulinum toxin” AND “trigeminal neuralgia”, and references of related articles were traced. Data on the efficacy
and safety of BTX-A in this disorder were extracted and analyzed by at least 2 reviewers. Data for individual studies
were reported, and pooled data were analyzed if appropriate. Five prospective studies and one double-blind,
randomized, placebo-controlled study were identified. Response was achieved in approximately 70-100% of
patients, and the mean pain intensity and frequency were reduced by approximately 60-100% at 4 weeks after
treatment in most studies. Major adverse events were not reported. Available studies show BTX-A may be effective
in treatment of trigeminal neuralgia. However, well-designed randomized, controlled, double-blinded trial is still
lacking. Future BTX-A treatment studies on optimal dose, duration of the therapeutic efficacy, common AEs, and
the time and indications for repeat injection would be promising.
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Introduction
Trigeminal neuralgia is a unilateral disorder character-
ized by brief electric shock-like pains, abrupt in onset
and termination, limited to the distribution of one or
more divisions of the trigeminal nerve [1]. Epidemio-
logical studies reveal that approximately 4-28.9/100,000
individuals worldwide experience TN [2-5]. It is the
most widely recognized neuropathic pain of the face and
has been shown to be profoundly distressing the pa-
tient’s well-being [6]. TN frequently occurs in subjects
aged 50-70 years and is more common in women [2,7].
Compression of the trigeminal nerve near the dorsal
root entry zone [8-12] by an overlaying blood vessel is a
major causative or contributing factor [8]. In addition, it
can also be caused by tumor, multiple sclerosis [13,14],* Correspondence: lingjingjin@hotmail.com
Department of neurology, Shanghai Tongji Hospital, Tongji University School
of Medicine, Xin-Cun Road 389, Shanghai 200065, China
© 2013 Hu et al.; licensee Springer. This is an O
Attribution License (http://creativecommons.or
in any medium, provided the original work is pinfiltration, amyloid [15-18], small infarcts or angiomas
in the pons or medulla [19-21]. In a small fraction of pa-
tients, the cause of TN cannot be identified [22].
The treatment of TN continues to be a major challenge
due to the complexity of TN’s causes and the trigeminal
nerve. The antiepileptic drugs, such as carbamazepine
[23,24] oxcarbazepine [25,26] and phenytoin [27,28], are
commonly used in the treatment of TN, but a substantial
proportion of patients have poor response to this treat-
ment, predominantly because of their side effects related
to the central nervous system [6]. Eventually, many TN
patients become refractory to antiepileptic drugs and
other drugs [29-32]. The quality of evidence on the effi-
cacy of neurosurgical procedures (such as percutaneous
interventions of the Gasserian ganglion, stereotactic radio-
surgery or microvascular decompression [33]) is very low.
Although these procedures may relieve the pain to differ-
ent extents, many may result in sensory side effects.pen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Figure 1 Flow chart illustrating the literature search
and evaluation.
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genically different botulinum neurotoxins derived from
Clostridium botulinum, appears to be the most potent
subtype [34]. It can cleave the synaptosome-associated
protein of 25 kDa (SNAP-25) in the motor nerve terminals
[35,36]. BTX-A is reported to be effective in the treatment
of migraine and myofacial pain syndrome [37-40]. The
mechanism of potential analgesic effect of BTX-A is still
unclear. In vitro studies have shown that BTX-A can in-
hibit the release of pro-inflammatory neuropeptides. Ani-
mal experiments also reveal the antinociceptive effect of
BTX-A in both inflammatory and neuropathic pain
models [41-47]. In 2002, Micheli et al reported the suc-
cessful treatment of a patient with hemifacial spasm asso-
ciated with TN with onabotulinumtoxin A, which opens
up new possibilities for its use [48]. After that, several
other open-label trials have examined the preventive ef-
fects of BTX-A on TN [49-51].
The current review is to systematically review the
therapeutic efficacy of BTX-A in TN. The secondary
goal of this review was to address the safety and toler-
ability of BTX-A in the treatment of TN.
Methods
The methodology utilized in this review followed the review
process derived from evidence-based systematic reviews
and meta-analyses [52-55] of clinic trials and semi-trials.
Literature search
A comprehensive search was conducted from 1966 to
2012 using databases including PubMed, EMBASE
(OVID), Cochrane Library Clinical Trials and Web of
Science. The PubMed, search was conducted by using
combinations of Medical Subject Heading (MeSH) search
terms and keywords according to the following algorithm:
(((“Trigeminal Neuralgia”[Mesh]) OR ((trigeminal [All
Fields]) AND neuralgia [All Fields]))) AND (((“Botulinum
Toxins, Type A”[Mesh] OR “Botulinum Toxins”[Mesh]))
OR botuli* [All Fields]). Other databases were queried by
using identical terms for keyword searching. The cross-
referencing of bibliographies from notable primary and re-
view articles, and abstracts from scientific meetings and
peer-reviewed non-indexed journals were also searched.
Only English articles were collected.
At least 2 authors independently, in an unblinded stan-
dardized manner, performed searching. Any disagree-
ments were resolved by a third author.
Criteria for inclusion of studies for review
All studies were reviewed by at least 2 reviewers for in-
clusion. Any disagreements were resolved by a third au-
thor. If there was a conflict of interest with the reviewed
manuscripts with authorship, the involved authors did
not review the manuscripts.Types of studies Randomized controlled trials, semi-
trials (case–control studies, open-label studies and case
series studies) were selected for evaluation the efficacy
and/or safety of BTX in the treatment of TN. When the
selected articles reported the same trial, only the latest
study with the largest sample size or longest follow-up
period was included.
Articles having no original data (such as letters, edito-
rials, commentaries and reviews) and those without ad-
equate information regarding the outcome were excluded.
Nonhuman studies were also excluded.Types of participants Patients with TN of all ages, sex,
and degrees of severity were included. TN was diagnosed
according to the criteria developed by the International
Headache Society (IHS) or other criteria that conformed
in general to the IHS diagnostic criteria [1].Types of interventions Included studies had to use ei-
ther a single dose of BTX-A to treat TN, or investigate
different dosing strategies. There was no restriction on
source of BTX-A, dose of administration, injection sites
or number of injections.Types of outcome measures The primary outcome
measure for this review was proportion of responders,
defined as patients with at least 50% reduction in fre-
quency and/or intensity of pain. For the secondary out-
comes of interests, we focused on the mean scores of
pain, mean attacks per day and treatment-related AEs.
Table 1 Characteristics of studies and patients for systematic review of BTX-A in the treatment of TN
















Wu et al. [56] 42 Randomised, double-blind,
placebo-controlled
1b 58.6 5.9 21.2 7.0 12 At least 12
Bohluli et al. [57] 15 Open-label 4 48.9 4.1 33.0 8.0 24 At least 24
Zúñiga et al. [58] 12 Open-label 4 58.5 6.2 23.4a 8.8a 8 At least 8
Türk et al. [59] 8 Open-label 4 57.1 1.6 unclear unclear 24 At least 24
Piovesan et al. [51] 13 Open-label 4 61.8 8.8 unclear 9.9 8 At least 8
Borodic et al. [60] 11 Open-label 4 54.2 b 10.0 unclear unclear 30.6b 5-12b
a the data of the 10 responded patients.




















Hu et al. The Journal of Headache and Pain 2013, 14:72 Page 4 of 8
http://www.thejournalofheadacheandpain.com/content/14/1/72Data extraction and management
A standardized form was used to extract the relevant
data on the patients’ and studies’ characteristics, injec-
tion protocol, clinical variables, and adverse events by 2
reviewers. Disagreements were resolved by discussion
among 3 reviewers.
Data interpretation
The extracted data were reviewed, interpreted, and
discussed to compile into level data according to “Oxford
Center for Evidence-based Medicine” criteria (http://www.
cebm.net/index.aspx?o=1025; updated March 2009) for
use in clinical practice. The outcome is integrated in the
Results and Discussion sections.
Results
Literature search
Figure 1 gives a flow diagram illustrating the results of the
literature search for BTX-A therapy in TN. After a com-
prehensive search, the references of several review articles
were checked, the available studies were evaluated, and
then 6 trials [51,56-60] were identified. Two studies of
Gazerani et al concerning BTX-A in the treatment of
capsaicin-evoked TN were not included in this review
[61,62].
Study characteristics
Table 1 illustrates the characteristics of studies on the
treatment of TN with BTX-A in this review. The number
of patients ranged from 8 to 42; and a total of 101 patients
were included in 6 selected studies. The majority of stud-
ies were open-label studies, except for Wu’s study [56], en-
rolled 42 patients, in double-blind, randomized and
placebo-controlled. Follow-up period ranged from 8 wk to
24 wk, except for a study evaluating the impact of re-
peated injections which lasted 16-80 wk [60].
Injection protocol
In most of the studies, the amount of BTX-A injected sub-
cutaneously was 20-50 U in the trigger zones (Table 2). In
Wu’s study [56], 75 U of BTX-A (Lanzhou BiologicalTable 2 Injection protocol of BTX-A
Author Source of BTX-A Amount o
BTX-A (U)
Wu et al. [56] Lanzhou Biological Products Institute, China 75
Bohluli et al. [57] Unclear 50
Zúñiga et al. [58] Botox 20-50
Türk et al. [59] Botox 100
Piovesan et al. [51] Unclear 6-9
Borodic et al. [60] Botox 30-50Products Institute) was used in each patient. In addition,
6-9 U and 100 U were used in two independent studies.Efficacy
Primary outcome The proportion of responders, de-
fined as patients with at least 50% reduction in fre-
quency and/or intensity of pain, was all above 60% and
the mean proportion was 80% (Figure 2). In Bohluli’s
study [57], patients with complete eradication of the
pain were also reported: the pain was completely eradi-
cated in 7 patients and there was no need for further
medication.Secondary outcomes In studies reporting the effect of
BTX-A on the pain intensity, the mean scores mea-
sured by VAS were between 7 and 10 at baseline
(Table 3). A controlled study demonstrated that the
therapeutic efficacy of BTX-A was significantly superior
to that of placebo in pain intensity [56]. Open-label tri-
als confirmed this trend [51,57-60]. After BTX-A injec-
tion, the reduction in the mean pain intensity from
baseline was 41-81% at 1 wk, 66-98% at 4 wk, about
80% at 8 wk and 12 wk.
A controlled study and open-label trials also demon-
strated that the therapeutic efficacy of BTX-A was sig-
nificantly superior to that of placebo in reducing daily
pain frequency (Table 4). The mean daily attacks were
21-33 at baseline, but 3.6-8.4 at 1 wk, 4.1-4.7 at 4 wk
and 1.8-2.3 at 8-12 wk after BTX-A injection. In
Piovesan’s study [51], the average pain area also signifi-
cantly reduced.
BTX-A was well tolerated in all 6 studies. Although
the local or systemic adverse events (AEs) were not very
well reported in all studies, most frequent AEs were
transient facial asymmetry (Table 5). Facial asymmetry
was not severe and resolved within 2 weeks in most
studies, except for one patient developing severe side ef-
fects which required physiotherapy and took 3 months
to resolve in Bohluli’s trial [57]. Other reported AEs of
BTX-A injection included transient edema (2.2%), eyelid
ptosis (1.1%), dysesthesia (1.1%) and difficulty in chewingf Injection sites No. of injections
Intradermal and/or submucosal trigger zones 15
Trigger zones Unclear
Subdermal trigger zones Unclear
Region of the zygomatic arch 2
Subdermal trigger zones Varied for each patient
Subdermal trigger zones Unclear
Table 3 Mean scores of pain measured by VAS
Author No. of patients Mean baseline (SD) Mean end point (SD) Mean change vs. baseline Mean % change vs. baseline
Wu et al. [56] placebo
week 1 20 6.9(2.3) 4.5 2.4 35
week 4 20 6.9(2.3) 4.7 2.2 32
week 8 20 6.9(2.3) 5.1 2.2 26
week 12 20 6.9(2.3) 5.3 1.6 23
Wu et al. [56] BTX-A
week 1 22 7.1(2.0) 4.2 2.9 41
week 4 22 7.1(2.0) 2.4 4.7 66a
week 8 22 7.1(2.0) 1.4 5.7 80a
week 12 22 7.1(2.0) 1.4 5.7 80a
Bohluli et al. [57]
week 1 15 8(1.9) 1.5(1.7) 6.5 81b
month 1 15 8(1.9) 1.2(1.4) 6.8 85b
Türk et al. [59]
week 1 8 Unclear Unclear Unclear Unclearb
month 2 8 Unclear Unclear Unclear Unclearb
month 6 8 Unclear Unclear Unclear Unclearb
Piovesan et al. [51] c
day 10 13 9.9(0.3) 5.0(3.9) 4.9 49b
day 20 13 9.9(0.3) 0.5(2.0) 9.4 95b
day 30 13 9.9(0.3) 0.2(1.0) 9.7 98b
day 60 13 9.9(0.3) 2.2(2.9) 7.7 78b
a p < 0.05 vs placebo.
b p < 0.05 vs baseline.
c mean of three different trigeminal branches.
Figure 2 Percent of patients responding to BTX-A treatment.
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Table 4 Mean attacks per day
Author No. of patients Mean at baseline (SD) Mean at the end (SD) Mean change vs. baseline Mean % change vs. baseline
Wu et al. [56] placebo
week 1 20 20.5(10.4) 18.5 2 10
week 4 20 20.5(10.4) 18.8 1.7 8
week 8 20 20.5(10.4) 17.7 2.8 14
week 12 20 20.5(10.4) 18.2 2.3 11
Wu et al. [56] BTX-A
week 1 22 21.7(22.7) 8.4 13.3 61a
week 4 22 21.7(22.7) 4.7 17 78a
week 8 22 21.7(22.7) 2.3 19.4 89a
week 12 22 21.7(22.7) 1.8 19.9 92a
Bohluli et al. [57]
week 1 15 33.0(18.9) 3.6(5.4) 29.4 89b
month 1 15 33.0(18.9) 4.1(5.8) 28.9 88b
Türk et al. [59]
week 1 8 Unclear Unclear Unclear Unclearb
month 2 8 Unclear Unclear Unclear Unclearb
month 6 8 Unclear Unclear Unclear Unclearb
a p < 0.05 vs placebo.
b p < 0.05 vs baseline.
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reported in all the 5 trials [51,56-60].
Analysis of evidence
The evidence for BTX-A in the treatment of TN was
quantified as Level 1b on the basis of one properly ran-
domized controlled trial and multiple open-label studies.
Discussion
From this systematic review, we can conclude that sub-
cutaneous or mucosal injection of BTX-A is effective for
adult TN patients.
Response was achieved in approximately 70-100% of
patients. In most studies, the mean pain intensity and
frequency were reduced by approximately 60-100% at
4 wk after injection. In Bohluli’s study [57], 47% of
patients didn’t need further treatment,; nonsteroidal
antiinflammatory drugs were enough to alleviate pain in
33% of patients, and 20% of patients again responded to
anticonvulsive drugs after BTX-A injection. In Piovesan’s
study [51], the pain area was reduced after injection.Table 5 Treatment-related AEs in the placebo-controlled
study of Wu et al [56]
Adverse events Placebo BTX-A
(n = 20) (n = 22)
Transient facial asymmetry 0 5 (23%)
Transient edema 1 (5%) 2 (9%)However, in the majority of studies, changes in medications
and pain area throughout the study were not clearly de-
scribed. A better understanding of this field requires more
studies In the future.
BTX-A has a faster onset of action with its significant
effect reaching within 1-2 wk and maximum effect
within 4-6 wk. Two studies suggest that the effect of a
single BTX-A injection could last for 6 mo or approxi-
mately 24 wk [57,59], whereas a few studies show the ef-
ficacy reduced at 4-8 wk after treatment. The duration
that the therapeutic effect continues should be studied
in future well designed trials.
Before injection, physicians should adequately inform
TN patients about the potential risk of BTX-A-related
AEs. Although BTX-A was well tolerated in TN patients,
transient facial asymmetry, transient edema, eyelid pto-
sis, dysesthesia and difficulty in chewing were still
reported in 6 studies. To adequately assess the incidence
of specific AEs and prevent the underestimate, future
studies should adequately document and report the local
and systemic AEs.
An important issue is, based on the currently available
evidence and physician experience, how BTX-A can be
best applied in clinical practice?
The first question is the dosage of BTX-A. The most
commonly used dose of BTX-A is 20-75 U. However,
Piovesan et al [51] found that 6-9 U of BTX-A induced
significant decreases in the pain area and intensity,
suggesting that lower doses are also feasible. Türk et al
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100 U of BTX-A. Because no study was designed to
compare the therapeutic efficacy of BTX-A at different
doses, the optimal dose cannot be concluded. Also, no
study was undertaken to compare of the efficacy or tol-
erance of BTX-A from different manufacturers.
Another variable is the number of injection sites. In
Wu’s study [56], injection was done at 15 sites. However,
injection was done at only 2 sites in Türk’s study [59]. It
is still unclear if the same efficacy with a less painful and
faster injection can be achieved by reducing the number
of injections with the same dose of BTX-A.
The optimal indications for re-injection are also im-
portant, but they weren’t clarified in these studies. In
our opinion, re-injection should be performed only when
the worsening of symptoms is present. Patients should
not receive repeated injections once the symptomatic
improvement occurs after two injections, or severe AEs
are present.
Conclusions
We speculate that BTX-A treatment may provide a clin-
ically significant benefit to TN adults. The effect is rap-
idly achieved, usually within 1-2 wk. Of importance,
BTX-A treatment seems to be well tolerated with min-
imal injections and to result in limited systemic adverse
events. Therefore, it represents a promising treatment of
TN with favorable risk-to-benefit ratio. However, well-
designed randomized, controlled, double-blinded trial is
still lacking. Future adequately powered studies are
needed to investigate the optimal dose of BTX-A treat-
ment, the duration of therapeutic efficacy, common AEs,
and the time and indications for repeat injection.
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